.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ05_Dulaglutide.Dulaglutide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ05_Dulaglutide.Dulaglutide| name: | Dulaglutide | |
| ATC code: | A10BJ05 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 1.5 | mg |
| volume of distribution: | 19.2 | L |
| clearance: | 0.114 | L/h |
| other parameters in model implementation | ||
Dulaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. It improves glycemic control by enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Dulaglutide is approved and in clinical use.
Pharmacokinetics in adult type 2 diabetic patients, following repeated subcutaneous administration. Parameters reflect pooled values from both sexes across multiple doses. Population PK analysis, mainly in adults aged 18-75, various ethnic groups.
Pratley, RE, et al., & Viljoen, A (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology 6(4) 275–286. DOI:10.1016/S2213-8587(18)30024-X PUBMED:https://pubmed.ncbi.nlm.nih.gov/29397376
Geiser, JS, et al., & de la Peña, A (2016). Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clinical pharmacokinetics 55(5) 625–634. DOI:10.1007/s40262-015-0338-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26507721
Zhang, Q, et al., & Hu, W (2023). Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Expert opinion on biological therapy 23(8) 727–735. DOI:10.1080/14712598.2023.2189009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36880118